Novartis | NOVN - Ebit


Novartis reported $5.14B in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Alcon AG USD 44M 253M Jun/2026
Almirall EUR 71.55M 41.32M Jun/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Autolus Therapeutics Ltd USD -59.51M 12.95M Mar/2026
Bayer EUR 129M 626M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Fresenius EUR 639M 80M Sep/2026
Fresenius Medical Care EUR 384M 96.55M Sep/2026
Genmab DKK 407M 221M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
GRIFOLS EUR 394M 34M Sep/2026
Hikma Pharmaceutical USD 348M 31M Dec/2025
J&J USD 6.47B 1B Sep/2026
Lakefront Biotherapeutics EUR -43.51M 20.19M Jun/2026
Lonza CHF 673M 54M Jun/2025
Merck EUR 1.1B 51M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 411M Sep/2026
Novartis USD 1.78B 2.4B Sep/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Orion EUR 209.9M 33.3M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Philips EUR 206M 435M Sep/2026
Recordati EUR 185.16M 45.95M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
UCB EUR 1.29B 571M Dec/2025